Actively Recruiting
HPV Genotype Attribution and Disease Burden of Anal Cancer in China
Led by Fudan University · Updated on 2026-02-12
300
Participants Needed
1
Research Sites
187 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To demonstrate HPV prevalence and its genotype distributions in anal cancer in China and to describe demographic and clinical features of HPV-related anal cancer in China; To describe the epidemiological characteristics ,trends and of disease burden of anal cancer in China
CONDITIONS
Official Title
HPV Genotype Attribution and Disease Burden of Anal Cancer in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with anal cancers
- Patients without radiation or chemotherapy prior to specimen collection
You will not qualify if you...
- Patients with HIV infection
- Patients with immunosuppression after solid organ transplantation
- Those who do not agree to specimen collection and testing
- For retrospective study cases, those without specimen
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, China, 200032
Actively Recruiting
Research Team
Y
Ying Zheng
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here